National Resilience, Parker Institute team to incubate cancer startups. Metropolitan AntiViral Drug Accelerator will focus on eight molecular features of SARS-CoV-2 to create novel oral antivirals.

The start-up is built around four business units – technology, manufacturing, R&D and therapeutics – based on internal and external expertise. Kriya will take its first gene therapies into the clinic in 2023. 

CEPI will provide up to $12.5m funding for Panacea Biotec and THSTI’s pan-beta coronavirus vaccine candidate, currently in the preclinical stage. Meanwhile, Panacea’s dengue and pneumococcal vaccines are on track for a 2023 launch.

Septerna’s platform purifies G-coupled protein receptors (GPCR) to identify new drug targeting sites and then uses technologies such as machine learning to find novel compounds against hard-to-reach GPCRs.